Credit Suisse Group Reiterates GBX 5,900 Price Target for AstraZeneca (LON:AZN)
Credit Suisse Group set a GBX 5,900 ($76.38) target price on AstraZeneca (LON:AZN) in a report issued on Friday, July 27th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other research analysts also recently issued reports about the company. Barclays set a GBX 6,500 ($84.14) price target on AstraZeneca and gave the company a buy rating in a report on Friday, May 11th. Berenberg Bank set a GBX 6,000 ($77.67) price target on AstraZeneca and gave the company a buy rating in a report on Tuesday, April 24th. Deutsche Bank reaffirmed a buy rating on shares of AstraZeneca in a report on Monday, April 9th. Jefferies Financial Group set a GBX 5,650 ($73.14) price target on AstraZeneca and gave the company a buy rating in a report on Friday, April 13th. Finally, JPMorgan Chase & Co. set a GBX 5,500 ($71.20) target price on AstraZeneca and gave the company a buy rating in a report on Friday, April 13th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of GBX 5,577.36 ($72.20).
Shares of AstraZeneca traded up GBX 31 ($0.40), reaching GBX 6,107 ($79.06), during midday trading on Friday, MarketBeat.com reports. 1,938,710 shares of the company’s stock traded hands, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.15) and a one year high of GBX 5,520 ($71.46).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Trading Penny Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.